dimethyl fumarate mylan
mylan ireland limited - dimetil-fumarát - a sclerosis multiplex, a relapszáló-remittáló - immunszuppresszánsok - dimethyl fumarate mylan is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis.
dimethyl fumarate accord
accord healthcare s.l.u. - dimetil-fumarát - multiple sclerosis, relapsing-remitting; multiple sclerosis - immunszuppresszánsok - dimethyl fumarate accord is indicated for the treatment of adult and paediatric patients aged 13 years and older with relapsing remitting multiple sclerosis (rrms).
dimethyl fumarate neuraxpharm
laboratorios lesvi s.l. - dimetil-fumarát - a sclerosis multiplex, a relapszáló-remittáló - immunszuppresszánsok - dimethyl fumarate neuraxpharma is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis.
dimethyl fumarate polpharma
zaklady farmafarmaceutyczne polpharma s.aceutyczne polpharma s.a. - dimetil-fumarát - a sclerosis multiplex, a relapszáló-remittáló - immunszuppresszánsok - dimethyl fumarate polpharma is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis.
dimethyl fumarate teva
teva gmbh - dimetil-fumarát - multiple sclerosis, relapsing-remitting; multiple sclerosis - immunszuppresszánsok - dimethyl fumarate teva is indicated for the treatment of adult and paediatric patients aged 13 years and older with relapsing remitting multiple sclerosis (rrms).
sebacil 75 mg/ml ráönto oldat sertések részére a.u.v.
elanco animal health gmbh - foxim - ráönto oldat - phoxime - sertés
terbisil 10 mg/g krém
richter gedeon nyrt. - terbinafin -
terbisil 250 mg tabletta
richter gedeon nyrt. - terbinafin - other emollients and protectives
terbisil kid 125 mg tabletta
richter gedeon nyrt. - terbinafin -
teysuno
nordic group b.v. - tegafur, gimeracil, oteracil - gyomor-daganatok - daganatellenes szerek - teysuno is indicated in adults:- for the treatment of advanced gastric cancer when given in combination with cisplatin (see section 5. - as monotherapy or in combination with oxaliplatin or irinotecan, with or without bevacizumab, for the treatment of patients with metastatic colorectal cancer for whom it is not possible to continue treatment with another fluoropyrimidine due to hand-foot syndrome or cardiovascular toxicity that developed in the adjuvant or metastatic setting.